Skip to content

SNAP-8: What the Human Patch Study Does—and Does Not—Show

SNAP-8 is acetyl octapeptide-3. Human research includes a multi-ingredient dissolving-microneedle patch, but that is not proof of isolated SNAP-8 efficacy or systemic injection safety.

By Peptide Mag Editorial. Updated . Source and review policy.

Identity
Acetyl octapeptide-3
Human evidence examined
24 enrolled, 21 completed; combination patch versus HA-only patch
Main limitation
Several active ingredients and a specialized delivery system

The Simple Truth

Why this exists and what it’s supposed to do.

SNAP-8 exists as a topical alternative to injecting a toxin into your face.

Expression lines form because muscles contract, and botulinum toxin blocks the signal that makes them contract. SNAP-8 is an eight-amino-acid peptide designed to interfere with the same signalling machinery.

What it is supposed to do: soften expression lines from a cream, so no needles and no clinic visit. That is its entire reason for being in skincare.

The published human evidence is one patch study, and what it shows is narrower than the marketing implies.

Name the peptide correctly

SNAP-8 is the name used for acetyl octapeptide-3. It should not be silently substituted for acetyl hexapeptide-8, commonly associated with Argireline. A paper about one ingredient is not automatically evidence for the other, and a shared cosmetic theme does not establish equivalent performance. Checking the exact ingredient is the first step in assessing a peptide claim.

The 2024 primary study discussed here identifies its ingredient as acetyl octapeptide-3 and describes a dissolving microneedle formulation. That specificity matters more than broad language such as cosmetic peptide or anti-aging peptide. It tells the reader what was actually tested and prevents research on a finished formulation from being presented as a universal property of the ingredient.

There is human research—but on a combination product

The investigators enrolled 24 adults with eye wrinkles; 21 completed the 28-day study. Participants received the active patch and a hyaluronic-acid-only comparison patch on opposite sides around the eyes. The active formulation combined acetyl octapeptide-3 with L-ascorbic acid 2-glucoside and sodium cyclic lysophosphatidic acid in a hyaluronic-acid microneedle matrix. It was not a trial of SNAP-8 alone.

The paper reports improvements in measured wrinkle-roughness endpoints relative to the comparison patch at day 28. No adverse effects were observed during that short study. This supports describing a promising result for the tested combination and delivery system. It does not identify how much benefit, if any, came from acetyl octapeptide-3 independently of the other ingredients.

A patch is not a cream, and neither is a systemic injection

Delivery is part of this intervention. Dissolving microneedles were designed to penetrate the skin barrier and release their contents locally. The physical patch, its hyaluronic-acid matrix and the other ingredients could all influence the observed response. The study therefore cannot be reduced to a claim that any preparation of the peptide will produce the same result.

An ordinary topical cosmetic, the tested patch and an injected research preparation are distinct products with distinct exposure conditions. This trial does not validate a systemic injection route, an injectable dose or a research-vendor vial. It also does not show that an online product has the identity, purity, sterility or formulation used by the investigators. Those questions require their own evidence rather than borrowing credibility from a different product.

What remains uncertain

The study was small and lasted four weeks. A short observation without recorded adverse effects is not proof of long-term safety. Multiple ingredients make the isolated effect uncertain, and several authors were affiliated with Raphas, the company involved in the technology. That affiliation is relevant context, not evidence that the reported results are fabricated; it strengthens the case for independent replication.

The most useful next study would distinguish the ingredient's contribution from its delivery system and coingredients. Until then, ingredient-level claims should remain narrower than the finished-product findings. Statements about reversing aging, replacing a medical procedure or producing predictable systemic effects go beyond what this study establishes.

Questions readers actually ask

Has SNAP-8 been studied in humans? Yes, it was included in the cited combination microneedle-patch study. Saying there is no human research would be inaccurate. Saying that the study proves SNAP-8 alone works would also be inaccurate. Both the positive observation and the attribution limit belong in the answer.

Is SNAP-8 the same as Botox? This patch study does not establish clinical equivalence to botulinum-toxin treatment or compare their efficacy and risks. Mechanistic analogies are not head-to-head clinical evidence. Does this support injecting SNAP-8? No injectable protocol follows from the tested skin patch. This guide does not provide a dosing, mixing or administration regimen, and the research result should not be used to turn a cosmetic ingredient into an implied approved medicine.

Sources and further reading

  1. Shin et al., 2024: combination dissolving microneedle patch study

Continue reading